ÂÜÀòÂÒÂ×

Craig Tooman joined Silence in January 2021 as the CFO and was appointed President, CEO, and Executive Director in February 2022.

He brings more than 30 years of operational, financial, and merger and acquisition ("M&A") experience. Most recently, he was Chief Operating Officer and CFO at Vyome Therapeutics, and prior to this was CEO of Aratana Therapeutics where he successfully negotiated a merger with Elanco. Before Aratana, Mr. Tooman was the CEO of Avanzar Medical Inc., a private oncology company, and CFO of Enzon Pharmaceuticals until its acquisition by Sigma Tau. Prior to that, he led the $1.1 billion M&A initiative and integration of ILEX Oncology and Genzyme Corporation. He also held key positions at Pharmacia and Upjohn.

Mr. Tooman currently serves on the Supervisory Board and Audit Committee of CureVac, which accomplished a successful initial public offering on Nasdaq in August of 2020.

He holds a BA in Economics from Kalamazoo College and an MBA from the University of Chicago.